Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | VHL | P40337 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072233 | 0.84 | HCAR2 (0.64) | HCAR2POLBNPC1RAB9AKMT2A | |
| SCHEMBL6074169 | 0.78 | CHRNA4 (0.43) | HCAR2POLBRAB9ACHRNA4SMN1; SMN2 | |
| SCHEMBL10518950 | 0.77 | GSK3B (0.38) | HCAR2POLBKMT2AALDH1A1MEN1 | |
| SCHEMBL8126016 | 0.77 | CHRNA4 (0.46) | HCAR2POLBKMT2ACHRNA4ALDH1A1 | |
| SCHEMBL1535177 | 0.76 | MAPT (0.49) | POLBNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL222184 | 0.75 | — | — | |
| SCHEMBL1613078 | 0.75 | — | — | |
| SCHEMBL10518042 | 0.74 | GSK3B (0.34) | HCAR2POLBCHRNA4ALDH1A1L3MBTL1 | |
| SCHEMBL353474 | 0.74 | — | — | |
| SCHEMBL1797269 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| EP-2867236-B1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS | PFIZER (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2867236-B1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS | PFIZER (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| WO-2000006606-A2 | ERYTHROMYCIN DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2000-02-10 | — | — | WO | disclosed |
| US-5705515-A | HAVING REDUCED SIDE EFFECTS | MERCK & CO., INC. (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0191045-B1 | USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES | ZAMBON S.p.A. (IT) | 1989-12-20 | — | — | EP | disclosed |
| EP-0190298-B1 | 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND DERIVATIVES THEREOF | ZAMBON S.p.A. (IT) | 1989-10-18 | — | — | EP | disclosed |
| US-4766137-A | 4-(isoxazolyl)-thiazole-2-oxamic acids and derivatives thereof | ZAMBON S.P.A. (IT) | 1988-08-23 | — | — | US | disclosed |
| US-4766138-A | Use of 4-(isoxazolyl)-thiazole-2-oxamic acid derivatives | ZAMBON S.P.A. (IT) | 1988-08-23 | — | — | US | disclosed |
| EP-0191045-A1 | USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES. | ZAMBON SPA (IT) | 1986-08-20 | — | — | EP | disclosed |
| EP-0190298-A1 | 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND DERIVATIVES THEREOF. | ZAMBON SPA (IT) | 1986-08-13 | — | — | EP | disclosed |
| WO-1986000899-A1 | USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES | ZAMBON S.P.A. (IT) | 1986-02-13 | — | — | WO | disclosed |
| WO-1986000900-A1 | 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND DERIVATIVES THEREOF | ZAMBON, S.P.A. (IT) | 1986-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | HCAR2 853/4885POLB 4081/4885NPC1 796/4885 |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | HCAR2 853/4885POLB 4081/4885NPC1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.